Biotechnology and Pharmaceutical Mini MBA Course

Name: Biotechnology and Pharmaceutical Mini MBA Training Course
Availability: InStock

Connect scientific evidence, portfolio priorities, operating realities, and commercial choices in decision-ready business cases.

Biotechnology and Pharmaceutical Mini MBA Course

At a glance

Duration: 1 Week
Format: Classroom
Cities: Seoul, Barcelona, Geneva, Montreux, Tokyo, Singapore and more
Next session: 2 – 6 November 2026, Seoul
Average fee: 5,750 €

Home
Our Categories
Biotechnology and Pharmaceutical Mini MBA Training Course

Download Brochure (PDF) Print PDF

Overview

Biotechnology and Pharmaceutical Mini MBA Training Course is a one-week course for managers, scientists entering leadership, project leaders, and technical specialists who leave with a Life Sciences Business Decision Portfolio. Participants connect biotechnology business models, pharmaceutical strategy, finance, portfolio choices, operations, quality risk, commercialization, market access, partnerships, innovation, and leadership. Agile Leaders Training Center presents biotechnology and pharmaceutical management as a cross-functional business discipline.

Who Should Attend

Scientific functions responsible for translating technical evidence into investment and portfolio decisions
Commercial functions responsible for market assessment, value propositions, launch, and market access
Operations functions responsible for manufacturing strategy, supply reliability, quality, and performance
Portfolio functions responsible for pipeline priorities, stage gates, resources, and lifecycle choices
Partnership functions responsible for licensing, alliances, due diligence, and governance
Leadership functions responsible for cross-functional alignment, innovation, and business performance

The course assumes participants already work in biotechnology, pharmaceuticals, or life-science services and leaves out laboratory science, clinical practice, legal advice, and product-specific submissions.

Departments and Industries

The course supports departments and industries that make strategy, investment, operating, and commercialization decisions in life sciences.

Biotechnology, biopharmaceutical, and pharmaceutical companies
Vaccine, diagnostics, and advanced-therapy organizations
Research, product-development, and portfolio departments
Manufacturing, quality, supply, and technology-transfer functions
Commercial, market-access, licensing, and alliance teams
Investment, advisory, contract-development, and service organizations

Learning Objectives

By the end of this course, participants will be able to:

Analyze biotechnology and pharmaceutical business models
Evaluate portfolio, pipeline, and investment tradeoffs
Build financial and value-creation cases for strategic choices
Compare operating, supply, quality, and partnership models
Prioritize commercialization and market-access pathways
Apply leadership governance to cross-functional execution

Course Agenda

Day 1: Strategy and Business Model Choices

Life Sciences Value Chain and Stakeholder Map
Biotechnology and Pharmaceutical Business Model Canvas
Competitive Position and Strategic Choice Matrix
Platform, Product, and Service Strategy Decision Tree
Strategic Assumption and Evidence Register

Day 2: Portfolio, Pipeline, and Finance

Pipeline Stage-Gate Governance Framework
Portfolio Attractiveness and Risk Scorecard
Probability-Adjusted Value and Scenario Model
Development Cost, Cash Flow, and Funding Map
Investment Committee Decision Memorandum

Day 3: Operations, Quality, and Supply

Development-to-Manufacturing Technology Transfer Map
Operating Model and Make-Buy-Partner Matrix
Quality Risk and Product Lifecycle Governance Map
Supply Network Resilience and Capacity Scenario Tool
Manufacturing Performance and Quality Metrics Dashboard

Day 4: Commercialization and Partnerships

Target Product and Customer Value Proposition Canvas
Market Segmentation and Access Pathway Map
Launch Sequence and Commercial Readiness Scorecard
Licensing and Alliance Structure Comparison Matrix
Partner Due Diligence and Governance Checklist

Day 5: Life Sciences Business Decision Practice

Exercise: Test a Biotechnology Business Model
Exercise: Prioritize a Pharmaceutical Pipeline
Exercise: Build an Investment and Operating Case
Exercise: Design a Commercialization and Partnership Route
Capstone Exercise: Life Sciences Business Decision Portfolio

Practical Exercises

The course uses suggested activities drawn from therapeutics, vaccines, diagnostics, biotechnology platforms, and contract services.

Suggested activity: compare platform, product, licensing, service, and partnership models against strategy and capability constraints.
Suggested activity: prioritize pipeline assets using evidence, risk, resource demand, strategic fit, and value scenarios.
Suggested activity: connect operating choices, quality risk, capacity, supply resilience, and financial consequences.
Suggested activity: integrate portfolio, finance, operations, commercialization, partnership, and leadership decisions in the capstone portfolio.

FAQs

Who suits a biotechnology and pharmaceutical Mini MBA course, and what does it assume?

A biotechnology and pharmaceutical Mini MBA course suits experienced technical, scientific, commercial, operational, and project professionals who already contribute to business decisions.

How does a biotechnology and pharmaceutical Mini MBA differ from a general management course?

A biotechnology and pharmaceutical Mini MBA applies strategy, finance, operations, portfolio, quality, commercialization, and partnership tools to life-science development and product-lifecycle decisions.

How are biotechnology portfolio decisions evaluated?

Biotechnology portfolio decisions combine evidence strength, development risk, strategic fit, resource demand, timing, operating feasibility, partnership options, and probability-adjusted value scenarios.

Why do quality and supply belong in pharmaceutical business strategy?

Quality and supply shape capacity, reliability, cost, risk, technology transfer, lifecycle performance, and the ability to deliver products consistently.

What makes a pharmaceutical commercialization case decision-ready?

A decision-ready pharmaceutical commercialization case connects target customers, value proposition, market access, evidence needs, launch sequence, operating capability, partnerships, investment, risks, and governance.

Conclusion

The course integrates biotechnology strategy, pharmaceutical finance, portfolio choices, operations, quality, commercialization, partnerships, innovation, and leadership. Participants take back a Life Sciences Business Decision Portfolio. The portfolio changes cross-functional decisions by making assumptions, evidence, economics, operating consequences, accountabilities, risks, and strategic choices explicit.

credits: 5 credit per day

Course Mode: full-time

Provider: Agile Leaders Training Center

Download Brochure (PDF) Print PDF

Showing 1-20 of 75 events

Location	Dates	Duration	Mode	Price
Seoul	Week 45, 2026 2 – 6 November 2026	1 Week	Onsite	€10,000
Barcelona	Week 46, 2026 9 – 13 November 2026	1 Week	Onsite	€5,700
Geneva	Week 46, 2026 15 – 19 November 2026	1 Week	Onsite	€6,200
Montreux	Week 47, 2026 16 – 20 November 2026	1 Week	Onsite	€7,500
Tokyo	Week 48, 2026 23 – 27 November 2026	1 Week	Onsite	€10,000
Singapore	Week 48, 2026 23 – 27 November 2026	1 Week	Onsite	€5,700
Vienna	Week 49, 2026 30 November – 4 December 2026	1 Week	Onsite	€5,700
Amsterdam	Week 50, 2026 7 – 11 December 2026	1 Week	Onsite	€5,700
Dubai	Week 51, 2026 14 – 18 December 2026	1 Week	Onsite	€4,500
Manama	Week 51, 2026 20 – 24 December 2026	1 Week	Onsite	€4,700
Abu Dhabi	Week 52, 2026 21 – 25 December 2026	1 Week	Onsite	€4,700
Lagos	Week 52, 2026 27 – 31 December 2026	1 Week	Onsite	€4,100
Paris	Week 53, 2026 28 December 2026 – 1 January 2027	1 Week	Onsite	€5,700
Dubai	Week 01, 2027 4 – 8 January 2027	1 Week	Onsite	€4,500
Berlin	Week 01, 2027 4 – 8 January 2027	1 Week	Onsite	€5,700
Trabzon	Week 01, 2027 10 – 14 January 2027	1 Week	Onsite	€6,800
Tbilisi	Week 02, 2027 11 – 15 January 2027	1 Week	Onsite	€5,000
Jakarta	Week 03, 2027 18 – 22 January 2027	1 Week	Onsite	€5,700
Chicago	Week 03, 2027 24 – 28 January 2027	1 Week	Onsite	€12,000
London	Week 04, 2027 25 – 29 January 2027	1 Week	Onsite	€5,700

Frequently asked questions

What does this course cover?

OverviewBiotechnology and Pharmaceutical Mini MBA Training Course is a one-week course for managers, scientists entering leadership, project leaders, and technical specialists who leave with a Life Sciences Business Decision Portfolio. Participants connect biotechnology business models, pharmaceutical strategy, finance, portfolio choices, operations, qual…

Are training dates available?

Yes. Available dates and destinations are listed in the course dates section on this page.

How can I register?

Choose an available date on this page and complete the registration form, or send a programme enquiry.

Can I download the course brochure?

Yes. Use the brochure download link provided on this page.

Biotechnology and Pharmaceutical Mini MBA Course